论文部分内容阅读
目的评价螺内酯治疗充血性心力衰竭(CHF)的治疗效果。方法将82例NYHAⅡ-Ⅳ级CHF患者随机分为两组,每组41例。对照组采用强心、利尿及血管紧张素转换酶抑制剂和倍他乐克治疗;观察组在对照组的基础上加用螺内酯25mg/d。疗程均为16周,观察两组治疗前后临床疗效。结果观察组临床显效率47.62%,有效率47.62%,无效率4.76%;对照组分别为40.47%、40.47%和19.05%(P<0.05)。治疗后与治疗前相比,两组心功能等指标均有显著性改善(P<0.001和P<0.05),血压与治疗前比较有下降。结论在充血性心力衰竭常规治疗基础上加用螺内酯治疗CHF是安全的,能改善心功能,提高患者活动耐量,减少心律失常发生。
Objective To evaluate the therapeutic effect of spironolactone in the treatment of congestive heart failure (CHF). Methods Eighty-two NYHA class Ⅱ-Ⅳ CHF patients were randomly divided into two groups, 41 cases in each group. The control group was treated with cardiotomy, diuretic and angiotensin converting enzyme inhibitors and metoprolol. The observation group was given spironolactone 25 mg / d on the basis of the control group. The course of treatment was 16 weeks, and the clinical effects of the two groups before and after treatment were observed. Results The effective rate of observation group was 47.62%, the effective rate was 47.62% and the inefficiency rate was 4.76%. The control group was 40.47%, 40.47% and 19.05% respectively (P <0.05). After treatment, compared with before treatment, heart function and other indicators were significantly improved (P <0.001 and P <0.05), blood pressure decreased compared with before treatment. Conclusion The treatment of CHF with spironolactone is safe on the basis of conventional treatment of congestive heart failure, which can improve cardiac function, increase patient activity tolerance and reduce arrhythmia.